Breaking News Instant updates and real-time market news.

VTVT

vTv Therapeutics

$4.59

-0.08 (-1.71%)

, BIIB

Biogen

$281.95

-0.65 (-0.23%)

04:55
07/20/17
07/20
04:55
07/20/17
04:55

Alzheimer's Association to hold a conference

Alzheimer's Association International Conference: AAIC 2017 will be held in London, England on July 16-20.

VTVT

vTv Therapeutics

$4.59

-0.08 (-1.71%)

BIIB

Biogen

$281.95

-0.65 (-0.23%)

AXON

Axovant Sciences

$23.06

0.03 (0.13%)

RHHBY

Roche

$31.96

0.11 (0.35%)

ACIU

AC Immune

$8.12

-0.12 (-1.46%)

JNJ

Johnson & Johnson

$135.21

0.75 (0.56%)

ABBV

AbbVie

$72.77

0.54 (0.75%)

AMGN

Amgen

$179.18

1.7 (0.96%)

NOV

National Oilwell

$35.15

1.27 (3.75%)

ESALY

Eisai

$53.62

-0.14 (-0.26%)

SNY

Sanofi

$46.81

-0.93 (-1.95%)

CORI

Corium

$8.95

-0.17 (-1.86%)

LLY

Eli Lilly

$84.23

0.53 (0.63%)

PFE

Pfizer

$33.62

0.26 (0.78%)

NTRP

Neurotrope

$5.80

-1.81 (-23.78%)

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 28

    Jul

  • 28

    Jul

  • 30

    Jul

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 09

    Aug

  • 14

    Aug

  • 27

    Aug

  • 29

    Aug

  • 11

    Sep

  • 14

    Sep

  • 03

    Feb

VTVT vTv Therapeutics
$4.59

-0.08 (-1.71%)

03/29/17
STFL
03/29/17
NO CHANGE
Target $14
STFL
Buy
vTv Therapeutics TTP399 safety data looked 'very promising,' says Stifel
Stifel analyst Thomas Shrader said the safety data from vTv Therapeutics' Phase 2 trial of TTP399 looked "very promising" and appear to him to be "strong enough" to drive a partnership, which is likely required for the next stages of the drug's development. Shrader keeps a Buy rating and $14 price target on vTv shares.
12/15/16
STFL
12/15/16
NO CHANGE
STFL
vTv Therapeutics price target raised to $14 from $12 at Stifel
Stifel analyst Thomas Shrader believes that vTv's TTP273 showed positive results in a Phase IIb trial of T2d patients. The analyst thinks that the drug " has demonstrated proof of concept with hints of an improved safety profile relative to Byetta." He predicts that vTv will obtain a partner for the drug and will receive " a $100M - $200M upfront payment and low double digit royalties on sales." Shrader keeps a Buy rating on the shares.
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
09/26/16
HCWC
09/26/16
INITIATION
Target $13
HCWC
Buy
vTv Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started vTv Therapeutics with a Buy rating and $13 price target.
BIIB Biogen
$281.95

-0.65 (-0.23%)

06/22/17
LEER
06/22/17
NO CHANGE
LEER
Leerink sees reasons for biotech rally to continue
Leerink analyst Geoffrey Porges attributes the recent strength in the biotech sector to a lessening of the perceived fears of pricing regulations and a favorable tone from the FDA. However, he believes the sector could advance at least 15% more, as he foresees more positive operating results and still expects more industry consolidation. Among large cap biotech names, Porges maintains Outperform ratings on Regeneron (REGN), Celgene (CELG), Vertex (VRTX) and Alexion(ALXN) and keeps Market Perform ratings on AbbVie (ABBV), Amgen (AMGN), Gilead (GILD) and Biogen (BIIB).
06/19/17
06/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/23/17
DBAB
06/23/17
INITIATION
Target $315
DBAB
Buy
Biogen initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Andrew Peters started Biogen with a Buy rating and $315 price target, as he sees meaningful top-line growth driven by the pipeline and recently approved products and also expects margin expansion. Peters also hold a favorable view on Biogen's pipeline optionality, he tells investors.
07/10/17
JEFF
07/10/17
INITIATION
Target $310
JEFF
Hold
Biogen assumed with a Hold at Jefferies
Jefferies analyst Michael Yee assumed coverage on Biogen with a Hold and a $310 price target.
AXON Axovant Sciences
$23.06

0.03 (0.13%)

07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Outperform
Axovant Sciences upcoming results may drive valuation upside, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Axovant Sciences faces two substantial binary events including the Phase 3 MINDSET study results at the end of September and the Phase 2 HEADWAY study results in Q4. The combination of these two events could drive up to 100% valuation upside, he contends. Further, the analyst believes the company is positioned to deliver the first new symptomatic Alzheimer's Disease drug approved by the FDA in over a decade. Olson reiterates an Outperform rating on the shares.
06/14/17
OPCO
06/14/17
NO CHANGE
Target $30
OPCO
Outperform
Axovant Sciences price target raised to $30 from $26 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Axovant Sciences to $30 after leaving a meeting with management "incrementally more positive." The analyst is "encouraged" by management's vision which he says extends beyond dementia into other areas of high unmet need within neurology. He believes the focus on dementia with Lewy bodies and Lewy body dementia, which includes Parkinson's disease dementia, could "create significant value for shareholders." Olson sees a favorable risk/reward profile for intepirdine in the Phase 3 Mindset study with top-line results due in late September. He keeps an Outperform rating on Axovant.
07/10/17
JEFF
07/10/17
INITIATION
Target $40
JEFF
Buy
Axovant Sciences initiated with a Buy at Jefferies
Jefferies analyst Michael Yee initiated Axovant Sciences with a Buy and a $40 price target.
04/17/17
JEFF
04/17/17
NO CHANGE
Target $31
JEFF
Buy
Jefferies sees Axovant shares hitting $5 or $90 on Sept. data
Jefferies analyst Biren Amin last week hosted investor meetings with Axovant Sciences' incoming CEO David Hung and Vivek Ramaswamy, who is transitioning to CEO of privately held Roivant. He notes the stock is up 45% since the announcement. "This is the stupidest thing I've ever heard," Hung said of the investor theory that he believes intepirdine will fail, Amin tells investors in a research note. It seems Axovant's profile fit what Hung was looking for and he conducted extensive due diligence on both intepirdine and nelotanserin, the analyst writes. He adds that the new CEO believes both products, in aggregate, offer five opportunities for value creation. Regarding the late September Phase III readout for intepirdine in mild to moderate Alzheimer's disease, Amin believes Axovant shares could trade to $80-$90 with strong improvement on the Alzheimer's disease assessment scale, or ADS-cog, of 1.5 point at 24 weeks and positive ADCS-adl, or Alzheimer's disease cooperative study - activities of daily living outcome. With a more moderate outcome where ADS-cog ranges between 0.7 and 1.3 point improvement and ADCS-adl does not achieve statistical significance, the analyst thinks the shares could still range higher to $45-$50. If the Mindset trial fails, he thinks the shares could drop to $5. Axovant closed Thursday up $2.20 to $22.
RHHBY Roche
$31.96

0.11 (0.35%)

07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.
07/06/17
UBSW
07/06/17
DOWNGRADE
UBSW
Neutral
Roche downgraded to Neutral from Buy at UBS
UBS analyst Jack Scannell downgraded Roche to Neutral saying he's become more cautious on oncology in general and that the shares are close to his fair value estimate. The analyst has a CHF 260 price target for the shares.
07/11/17
FBCO
07/11/17
NO CHANGE
Target $96
FBCO
Outperform
Alnylam weakness more driven by competitor data, says Credit Suisse
While attending the ISTH meeting in Berlin, Credit Suisse analyst Alethia Young notes that Alnylam's (ALNY) stock weakness is more driven by "strong" competitor data in inhibitors from Roche's (RHHBY) ACE910. The analyst reiterates an Outperform rating and $96 price target on Alnylam's shares.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
ACIU AC Immune
$8.12

-0.12 (-1.46%)

10/18/16
10/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Costco (COST) initiated with a Market Perform at Wells Fargo. 2. Level 3 (LVLT) initiated with an Overweight at Barclays. 3. AC Immune (ACIU) initiated with a Buy at Jefferies, an Outperform at Credit Suisse, and an Outperform at Leerink. 4. Apptio (APTI) initiated with a Neutral at Goldman, a Buy at Jefferies, an Equal Weight at Barclays, a Neutral at JPMorgan, a Buy at BofA/Merrill, an Overweight at Pacific Crest, and a Sector Perform at RBC Capital. 5. Adient (ADNT) initiated with an Outperform at Baird, a Neutral at Buckingham, and a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/16
FBCO
10/18/16
INITIATION
Target $18
FBCO
Outperform
AC Immune initiated with an Outperform at Credit Suisse
Credit Suisse analyst Alethia Young initiated AC Immune with an Outperform and a $18 price target due to the opportunity for lead asset, crenezumab primarily for Alzheimer's Disease, in Phase 3 in partnership with Roche.
10/18/16
JEFF
10/18/16
INITIATION
Target $25
JEFF
Buy
AC Immune initiated with a Buy at Jefferies
Jefferies analyst Peter Welford started AC Immune with a Buy rating and $25 price target. The company may have the broadest Alzheimer's pipeline in biotech, Welford tells investors in a research note.
10/18/16
LEER
10/18/16
INITIATION
Target $22
LEER
Outperform
AC Immune initiated with an Outperform at Leerink
Leerink analyst Paul Matteis started AC Immune with an Outperform rating and $22 price target, citing its expanding basket of high risk/high reward Alzheimer's Disease opportunities.
JNJ Johnson & Johnson
$135.21

0.75 (0.56%)

07/19/17
UBSW
07/19/17
NO CHANGE
Target $148
UBSW
Buy
Johnson & Johnson price target raised to $148 from $136 at UBS
UBS analyst Matt Miksic raised his price target on Johnson & Johnson to $148 from $136 following solid Q2 earnings. The analyst noted the company raised guidance and said its second half growth profile is improving. The analyst raised his 2018 projected EBITDA and multiple, leading to his higher price target, and reiterated his Buy rating on J&J shares.
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
ABBV AbbVie
$72.77

0.54 (0.75%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
AbbVie should be bought on weakness, says SunTrust
SunTrust analyst John Boris says that AbbVie should be bought on weakness after the USPTO invalidated two of the company's patents for Humira. The analyst says that the ruling "makes a small dent" in the company's IP for Humira, as he notes that the company has more than 100 patents for the drug. He thinks that Humira biosimilars will enter the market later than the Street expects. Boris, maintaining that the company has over a dozen pipeline catalysts this year, recommends buying the shares on weakness.
06/22/17
SOCG
06/22/17
UPGRADE
SOCG
Buy
AbbVie upgraded to Buy from Hold at Societe Generale
AMGN Amgen
$179.18

1.7 (0.96%)

07/18/17
PIPR
07/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper says Array deal with Amgen 'another example' of successful partnering
Commenting on Array Biopharma's (ARRY) announcement of a preclinical autoimmune partnership deal with Amgen (AMGN), Piper Jaffray analyst Edward Tenthoff called the agreement "yet another example of Array successfully partnering its discoveries" and raising non-dilutive capital. Tenthoff keeps an Overweight rating and $14 price target on Array Biopharma shares.
07/18/17
CHLM
07/18/17
NO CHANGE
Target $160
CHLM
Buy
Craig-Hallum sees Ligand agreement with Amgen as 'incrementally' positive news
Craig-Hallum analyst Matt Hewitt notes that Ligand (LGND) announced that it had entered into a new commercial license and supply agreement with Amgen (AMGN) for the use of the former's Captisol technology in the formulation of AMG 330, a bispecific antibody being investigated as a treatment for acute myeloid leukemia. The analyst believes this agreement signals AMG 330 moving from Phase 1 into Phase 2 trials and incrementally positive news for Ligand as this news was not anticipated in his model. Hewitt reiterates a Buy rating and $160 price target on Ligand's shares.
07/17/17
JEFF
07/17/17
NO CHANGE
Target $195
JEFF
Buy
Amgen Complete Response Letter was expected, says Jefferies
Jefferies analyst Michael Yee says the FDA's Complete Response Letter for Amgen's Romosozumab in osteoporosis was expected. The indication is not in current consensus near-term estimates given the prior known imbalance in safety signal, Yee tells investors in a research note. He believes the drug could still be approved in 2018-2019 based on a good risk/benefit profile. The analyst has a Buy rating on Amgen with a $195 price target.
07/10/17
JEFF
07/10/17
INITIATION
Target $195
JEFF
Buy
Amgen assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage on Amgen with a Buy and a $195 price target.
NOV National Oilwell
$35.15

1.27 (3.75%)

04/06/17
RFLF
04/06/17
INITIATION
Target $39
RFLF
Hold
National Oilwell initiated with a Hold at RF Lafferty
RF Lafferty initiated National Oilwell with a Hold and a $39 price target.
03/03/17
ARGS
03/03/17
UPGRADE
Target $51
ARGS
Buy
National Oilwell upgraded to Buy from Hold at Argus
Argus analyst Bill Selesky upgraded National Oilwell to Buy and set a price target of $51 citing the narrower than expected Q4 net loss, management's optimism about the U.S. land market on the conference call, and his expectations for a gradual increase in rig activity.
02/23/17
MSCO
02/23/17
NO CHANGE
Target $60
MSCO
Overweight
National Oilwell price target raised to $60, bull case to $100 at Morgan Stanley
Morgan Stanley analyst Ole Slorer said National Oilwell is a top-tier global franchise due to its market leadership, margins, and free cash flow story, yet trades at a discounted valuation to other market leaders, despite comparable free cash flow generation. Slorer said National is shifting its focus towards increased exposure to capex across the oilfield services value chain and away from offshore rig building. He believes the market is underestimating the earnings power from international rig retooling, US equipment revamp, and offshore rig maintenance and its new profile will help narrow the valuation gap. Slorer raised National Oilwell's price target to $60 from $45, and his bull case to $100, and reiterated his Overweight rating.
06/20/17
PIPR
06/20/17
UPGRADE
Target $37
PIPR
Overweight
National Oilwell upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Bill Herbert upgraded National Oilwell to Overweight saying the company's reliable execution, free cash flow generation and balance sheet strength should warrant a valuation premium over the next year. The analyst raised his price target for the shares to $37 from $36.
ESALY Eisai
$53.62

-0.14 (-0.26%)

02/15/17
LEER
02/15/17
NO CHANGE
LEER
Biogen outlook intact despite Merck study suspension, says Leerink
Leerink analyst Geoffrey Porges notes that Merck (MRK) announced the suspension of the Phase 2/3 EPOCH trial of verubecestat in mild-to-moderate Alzheimer's patients for lack of efficacy, which was one of the most important catalysts for the field this year and a significant overhang for Biogen (BIIB) and other companies. While the failure had been widely anticipated in this study, the analyst believes this result does not read over to the outlook for Biogen's ongoing pivotal trials with aducanumab, or with its partner, Eisai's (ESALY) BACE inhibitor, elenbecestat.
01/05/17
JMPS
01/05/17
NO CHANGE
JMPS
Market Perform
JMP Securities views Arena amended agreement with Eisai 'favorably'
JMP Securities analyst Jason Butler says Arena Pharmaceuticals' (ARNA) amended agreement with Eisai (ESALY) reduces resource and capital constraints on the company while maintaining "attractive" long-term upside from Belviq success. The analyst notes that Eisai will now have full global development and marketing rights to Belviq in exchange for lowering Arena's royalties and cost contributions, which he views "favorably" as the commercial potential for it remains limited. Furthermore, the new agreement allows Arena to further focus its energies and resources in its Phase 2 pipeline assets, Butler adds. He reiterates a Market Perform on Arena Pharmaceuticals' shares.
SNY Sanofi
$46.81

-0.93 (-1.95%)

07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.
06/27/17
FBCO
06/27/17
NO CHANGE
FBCO
Outperform
Alnylam price target raised to $96 from $90 at Credit Suisse
Credit Suisse analyst Alethia Young increased her probability of success for Alnylam's (ALNY) givosian in porphyria to 60% from 40% and keeps an estimate of unadjusted peak sales of $475M, while also noting that the fact that Sanofi (SNY) did not opt into the porphyria program, meaning Alnylam receives full economics. Given the higher chances ascribed to success, Young raised her price target on Alnylam to $96 from $90 and keeps an Outperform rating on the stock.
CORI Corium
$8.95

-0.17 (-1.86%)

12/16/16
CANT
12/16/16
INITIATION
Target $10
CANT
Overweight
Corium initiated with an Overweight at Cantor
Cantor Fitzgerald analyst William Tanner started Corium with an Overweight rating and $10 price target.
01/04/17
LEER
01/04/17
NO CHANGE
Target $14
LEER
Outperform
Leerink lowers Corium target on lower probability of success for Twirla
Leerink analyst Jason Gerberry says Agile Therapeutics (AGRX) announced Phase 3 top-line data for Twirla, a levonorgestrel and ethinyl estradiol transdermal patch contraceptive. Noting that Corium (CORI) is Agile's manufacturer partner, the analyst lowered his price target on the former's shares to $14 from $16 and reduced his peak sales projection and probability of success for Twirla to 35% from 75%. He reiterates an Outperform rating on Corium's stock.
12/22/16
NEED
12/22/16
NO CHANGE
NEED
AMAG Pharmaceuticals, Corium top pharma picks for 2017 at Needham
Needham analyst Serge Belanger says that while 2016 kicked off with "the wrong kind of bang" for specialty pharma/biopharma equities, with the unraveling of the rollup strategies espoused by Valeant Pharmaceuticals (VRX) and Endo (ENDP) and the political rhetoric around drug pricing as headwinds throughout the year, the election outcome provides a more positive outlook for 2017. Nonetheless, the analyst believes the political uncertainty around drug pricing is likely to remain an ongoing but diminished concern with the new administration. Additionally, he expects some of the proposed tax changes of the new administration to be key drivers for driving M&A volumes in 2017 and beyond. Belanger believes this bodes well for companies in the classic spec pharma therapeutics areas that have historically benefited from consolidation, and said his top picks for 2017 are AMAG Pharmaceuticals (AMAG) and Corium (CORI).
LLY Eli Lilly
$84.23

0.53 (0.63%)

06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
07/17/17
PIPR
07/17/17
NO CHANGE
Target $102
PIPR
Overweight
Eli Lilly's launch in type 2 diabetes 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Richard Purkiss is highlighting the "remarkable growth story" of Eli Lilly's (LLY) once-weekly GLP-1 agonist Trulicity for type 2 diabetes. At its current pace, Trulicity would become market leader in the GLP-1 space in the early part of next year, surpassing Novo Nordisk's (NVO) Victoza, Purkiss tells investors in a research note. He views Lilly's launch as "quite simply unique in the current climate." Lilly remains one of the analyst's top 2017 picks with an Overweight rating and $102 price target.
PFE Pfizer
$33.62

0.26 (0.78%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
06/29/17
JEFF
06/29/17
UPGRADE
Target $117
JEFF
Buy
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy saying the shares continue to trade at a group discount. The analyst sees "solid appreciation potential" as Pfizer (PFE) concentration is reduced and potentially 45% upside with a more aggressive acquisition strategy. The company's management has talked more openly about larger deals, Windley tells investors in a research note. Windley raised his price target for Icon shares to $117 from $86.
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
NTRP Neurotrope
$5.80

-1.81 (-23.78%)

04/12/17
AGIS
04/12/17
INITIATION
Target $31
AGIS
Buy
Neurotrope initiated with a Buy at Aegis
Aegis analyst Robert LeBoyer started Neurotrope with a Buy rating and $31 price target.

TODAY'S FREE FLY STORIES

NKE

Nike

$52.30

0.3 (0.58%)

05:11
10/19/17
10/19
05:11
10/19/17
05:11
Downgrade
Nike rating change  »

Nike downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

GSBC

Great Southern Bancorp

$56.80

0.25 (0.44%)

05:10
10/19/17
10/19
05:10
10/19/17
05:10
Earnings
Great Southern Bancorp reports preliminary Q3 EPS 82c, consensus 82c »

Reports preliminary Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TERP

TerraForm Power

$13.58

0.62 (4.78%)

05:06
10/19/17
10/19
05:06
10/19/17
05:06
Initiation
TerraForm Power initiated  »

TerraForm Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$55.77

0.71 (1.29%)

05:04
10/19/17
10/19
05:04
10/19/17
05:04
Recommendations
Abbott analyst commentary  »

Abbott price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$187.15

-10.63 (-5.37%)

05:00
10/19/17
10/19
05:00
10/19/17
05:00
Recommendations
Allergan analyst commentary  »

Allergan price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

MERC

Mercer

$13.50

-0.05 (-0.37%)

04:58
10/19/17
10/19
04:58
10/19/17
04:58
Upgrade
Mercer rating change  »

Mercer upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ADBE

Adobe

04:57
10/19/17
10/19
04:57
10/19/17
04:57
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

ANGI

Angie's List

04:57
10/19/17
10/19
04:57
10/19/17
04:57
Upgrade
Angie's List rating change  »

Angie's List…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

GWW

Grainger

$208.81

3.39 (1.65%)

04:57
10/19/17
10/19
04:57
10/19/17
04:57
Downgrade
Grainger rating change  »

Grainger downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MZOR

Mazor Robotics

$58.55

3.57 (6.49%)

, NUVA

NuVasive

$54.18

0.47 (0.88%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Downgrade
Mazor Robotics, NuVasive rating change  »

Mazor Robotics downgraded…

MZOR

Mazor Robotics

$58.55

3.57 (6.49%)

NUVA

NuVasive

$54.18

0.47 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

MTCH

Match Group

$25.52

-0.56 (-2.15%)

, IAC

IAC

$124.60

-0.55 (-0.44%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Jefferies Internet analysts hold an analyst/industry conference call »

Internet Analysts…

MTCH

Match Group

$25.52

-0.56 (-2.15%)

IAC

IAC

$124.60

-0.55 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 08

    Nov

  • 09

    Nov

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Breaking General news story  »

Week of 10/13 EIA Natural…

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Breaking General news story  »

Week of 10/18 Fed Balance…

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Breaking General news story  »

Week of 10/9 Money Supply…

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

UBS

UBS

$17.26

0.02 (0.12%)

, CME

CME Group

$136.37

0.18 (0.13%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Futures Industry Association to hold an expo »

33rd Annual FIA Futures…

UBS

UBS

$17.26

0.02 (0.12%)

CME

CME Group

$136.37

0.18 (0.13%)

NDAQ

Nasdaq

$74.60

-0.11 (-0.15%)

ICE

IntercontinentalExchange

$68.20

0.03 (0.04%)

CBOE

CBOE Holdings

$109.59

0.06 (0.05%)

BAC

Bank of America

$26.48

0.28 (1.07%)

GS

Goldman Sachs

$242.03

5.94 (2.52%)

JPM

JPMorgan

$97.99

0.37 (0.38%)

CS

Credit Suisse

$15.91

-0.11 (-0.69%)

C

Citi

$73.12

0.93 (1.29%)

AMZN

Amazon.com

$997.00

-12.13 (-1.20%)

MS

Morgan Stanley

$50.15

1.03 (2.10%)

WFC

Wells Fargo

$53.41

0.22 (0.41%)

AMTD

TD Ameritrade

$47.54

0.32 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 02

    Nov

  • 02

    Nov

  • 05

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 20

    Nov

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 18

    Mar

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

SNY

Sanofi

$49.53

-0.06 (-0.12%)

, PFE

Pfizer

$35.83

-0.37 (-1.02%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Drug Information Association to hold a conference »

Metrics in…

SNY

Sanofi

$49.53

-0.06 (-0.12%)

PFE

Pfizer

$35.83

-0.37 (-1.02%)

ALKS

Alkermes

$51.09

-0.39 (-0.76%)

LLY

Eli Lilly

$85.73

-0.33 (-0.38%)

BMY

Bristol-Myers

$63.70

-0.48 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 20

    Oct

  • 20

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

VPG

Vishay Precision

$24.40

0.55 (2.31%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Vishay Precision management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 07

    Nov

SCS

Steelcase

$15.30

0.1 (0.66%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Steelcase management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 25

    Oct

  • 26

    Oct

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Philadelphia Fed Business Outlook Survey General Conditions Index to be reported at 08:30 »

October Philadelphia Fed…

SB

Safe Bulkers

$3.12

-0.01 (-0.32%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Safe Bulkers management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

COST

Costco

$157.55

-0.83 (-0.52%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55
Conference/Events
Costco management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Breaking General news story  »

Kansas City Federal…

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Breaking General news story  »

Week of 10/15 Bloomberg…

04:55
10/19/17
10/19
04:55
10/19/17
04:55
General news
Leading Indicators to be reported at 10:00 »

September Leading…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.